All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-06-03T15:29:49.000Z

ASCO 2019 | How do racial disparities affect multiple myeloma treatment?

Bookmark this article

Sikander Ailawadhi, Mayo Clinic, Jacksonville, US, talks to the MM Hub at ASCO 2019, about how racial disparities influence the outcomes of patients with multiple myeloma.

Sikander Ailawadhi discusses the growing complexity in defining racial subgroups, and highlights the need for an acceptance across institutions that the care we deliver is not uniform and this is leading to differences in patient outcomes. He highlights the next step will be to determine whether these underlying factors are the same across all subgroups, or are unique, and then to determine the best route to overcome them. To overcome these issues will involve opening a wider discussion, which this session at ASCO has taken great strides towards achieving.

How do racial disparities affect multiple myeloma treatment?

Your opinion matters

As a result of this content, I commit to reviewing the CARTITUDE clinical program to guide my understanding of cilta-cel in clinical practice.
19 votes - 12 days left ...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox